Ny antiinflammatorisk data för NeuroRestore ACD856 på Alzheimerskonferensen CTAD
AlzeCure Pharma develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer’s disease and pain, today announced that the company’s presentation at the Alzheimer’s conference CTAD 2024 is now available in its entirety on the company’s website. The presentation contains new preclinical data with the company’s leading clinical drug candidate NeuroRestore ACD856, which is being developed with a focus on Alzheimer’s disease, and being prepared for phase II.
”These new data suggest that ACD856 may play an anti-inflammatory and immunoregulatory role, in addition to the memory-enhancing and disease-modifying effects we have previously presented, and demonstrate its potential to slow neurodegeneration in Alzheimer’s and other diseases characterized by neuroinflammation,” said Dr. Cristina Parrado-Fernández, Senior Scientist at AlzeCure Pharma.
The presentation, titled Preclinical evidence for anti-inflammatory and immunomodulatory effects of NeuroRestore ACD856, a Trk-PAM in clinical development for the treatment of Alzheimer’s disease, was held by Dr. Parrado-Fernández and includes new preclinical data with ACD856, the lead clinical drug candidate in the NeuroRestore platform.
The new preclinical results with ACD856 show, among other things, that the substance can reduce and normalize the high levels of various inflammatory markers, including IL-6, IL-1b and IgG, in animal models of Alzheimer’s and aging. These anti-inflammatory effects have specific relevance to Alzheimer’s disease, where neuroinflammation is an important key finding in the disease.
Previous preclinical studies have shown that AlzeCure’s drug candidates in the NeuroRestore platform strengthen communication between nerve cells and improve cognitive ability, including learning and memory functions. Preclinical results from AlzeCure also show neuroprotective, anti-inflammatory and disease-modifying effects in various models with these so-called Trk-PAM substances. The unique pharmacological mechanism of NeuroRestore also enables several indications, such as Alzheimer’s and Parkinson’s disease, but also depression. ACD856 is a first-in-class drug candidate for Alzheimer’s disease and is now being prepared for upcoming phase II clinical studies in patients.
“These new findings with NeuroRestore ACD856 have relevance not only for Alzheimer’s, but also for other neurodegenerative diseases, such as Parkinson’s and frontal lobe dementia. The results strengthen our commercial opportunities for ACD856, which we are now planning for phase II clinical studies in patients,” said Martin Jönsson, CEO of AlzeCure Pharma.
The poster is available on AlzeCure’s website (https://www.alzecurepharma.se/en/presentations-and-interviews).
